Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
Pricing & Reimbursement
Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%
The premium headline is real, but part of the cost has moved from the monthly bill to the point of care.
Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.
IQWiG and LSE Authors Say EU Joint Clinical Assessments Could Become a Basis for US Price Talks
A debate about who sets the evidence bar, landing the same week Germany’s health ministry proposed lowering it.
The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
The plan lowers the evidence bar at launch and moves the proof to later real-world data, where insurers doubt it exists.
AbbVie’s Juvmo Won FDA Approval Three Days Before ICER Holds a Public Meeting on Its Value
AbbVie now has to name a price for Juvmo into a benchmark that ICER set before the drug was even approved.
Japan Clears Five Products in a Day, Two With a Price Cut Attached
Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.
GENEROUS Signings Jump From Seven to 40 States in a Week
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Korea Repriced 36 Fewer Items This Year and Took Out the Same ₩33.9 Billion
Thirty-six fewer items produced the same saving. Nothing about efficacy changed. The medicines that grew paid for it.